Effects of cobalt and chromium ions at clinically equivalent concentrations after metal-on-metal hip replacement on human osteoblasts and osteoclasts: implications for skeletal health by Andrews, R.E. et al.
promoting access to White Rose research papers 
   
White Rose Research Online 
eprints@whiterose.ac.uk 
 
 
 
Universities of Leeds, Sheffield and York 
http://eprints.whiterose.ac.uk/ 
 
 
 
This is an author produced version of a paper published in Bone.  
 
 
White Rose Research Online URL for this paper: 
http://eprints.whiterose.ac.uk/43430  
 
 
 
Published paper 
 
Andrews, R.E., Shah, K.M., Wilkinson, J.M., Gartland, A. (2011) Effects of cobalt 
and chromium ions at clinically equivalent concentrations after metal-on-metal 
hip replacement on human osteoblasts and osteoclasts: implications for skeletal 
health, Bone, 49 (4), pp. 717-723 
http://dx.doi.org/10.1016/j.bone.2011.06.007  
 
 
Effect of metal ions on osteoblasts and osteoclasts 
1 
 
Effects of Cobalt and Chromium Ions at Clinically Equivalent 
Concentrations after Metal-on-Metal Hip Replacement on Human 
Osteoblasts and Osteoclasts: Implications for Skeletal Health 
aRebecca E. Andrews*, a,bKaran M. Shah*, a,bJ Mark Wilkinson, and aAlison Gartland. 
aThe Mellanby Centre for Bone Research, Department of Human Metabolism, The 
University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, United Kingdom; bThe 
National Institute for Health Research Biomedical Research Unit for Musculoskeletal 
Disease at the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation 
Trust, Centre for Biomedical Research, Northern General Hospital, Herries Road, 
Sheffield, S5 7AU, United Kingdom 
*Equal contribution 
 
Corresponding author: JM Wilkinson 
Address: NIHR Biomedical Research Unit for Musculoskeletal Disease, Centre for 
Biomedical Research, Northern General Hospital, Herries Road, Sheffield, S5 7AU, United 
Kingdom 
Email: j.m.wilkinson@sheffield.ac.uk 
Phone +44 114 2714705 
Fax: +44 114 2618775 
 
Effect of metal ions on osteoblasts and osteoclasts 
2 
 
ABSTRACT 
Metal-on-metal hip replacement (MOMHR) using large diameter bearings has become a 
popular alternative to conventional total hip arthroplasty, but is associated with elevated 
local tissue and circulating levels of chromium (Cr) and cobalt (Co) ions that may affect 
bone health. We examined the effects of acute and chronic exposure to these metals on 
human osteoblast and osteoclast formation and function over a clinically relevant 
concentration range previously reported in serum and within hip synovial fluid in patients 
after MOMHR. SaOS-2 cells were cultured with Co2+, Cr3+ and Cr6+ for 3 days after which 
an MTS assay was used to assess cell viability, for 13 days after which alkaline 
phosphatase and cell viability were assessed and 21 days after which nodule formation 
was assessed. Monocytes were isolated from human peripheral blood and settled onto 
dentine disks then cultured with M-CSF and RANKL plus either Co2+, Cr3+ or Cr6+ ions for 
21 days from day 0 or between days 14 and 21. Cells were fixed and stained for TRAP 
and osteoclast number and amount of resorption per dentine disk determined. Co2+ and 
Cr3+ did not affect osteoblast survival or function over the clinically equivalent 
concentration range, whilst Cr6+ reduced osteoblast survival and function at concentrations 
within the clinically equivalent serum range after MOMHR (IC50 =2.2µM). In contrast, 
osteoclasts were more sensitive to metal ions exposure. At serum levels a mild stimulatory 
effect on resorption in forming osteoclasts was found for Co2+ and Cr3+, whist at higher 
serum and synovial equivalent concentrations, and with Cr6+, a reduction in cell number 
and resorption was observed. Co2+ and Cr6+ within the clinical range reduced cell number 
and resorption in mature osteoclasts. Our data suggests that metal ions at equivalent 
concentrations to those found in MOMHR affect bone cell health and may contribute to the 
observed bone-related complications of these prostheses. 
Key words: metal-on-metal hip replacement, hip resurfacing, cobalt, chromium, human 
osteoblast, human osteoclast.  
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1 INTRODUCTION 
In recent years total hip replacement using large diameter metal-on-metal bearings 
(MOMHR), either as a hip resurfacing procedure or using a stemmed femoral prosthesis, 
has become a common alternative to conventional total hip arthroplasty (THA) for the 
treatment of young and active arthritis patients because of advantages of lower volumetric 
wear and dislocation risk [1]. However, the clinical outcomes of hip replacement using 
these prostheses have been mixed. Data from the National Joint Register for England and 
Wales (2008) demonstrated a 3-year revision rate for hip resurfacing of 4.4% (95%CI 4.0 
to 5.0) compared with 1.3% (1.2 to 1.4) for cemented THA (www.njrcentre.org.uk). The 
Australian arthroplasty register (1997 to 2005) also reported a higher 3-year revision rate 
for hip resurfacing versus THA (3.1% (2.7 to 3.6) versus 2.1% (1.9 to 2.5%) 
www.dmac.adelaide.edu.au/aoanjrr). The most common adverse events necessitating 
revision surgery after MOMHR include early periprosthetic fracture, osteolysis, failure of 
prosthesis osseo-integration resulting in aseptic loosening, unexplained pain, and 
inflammatory masses [2-7]. 
Circulating physiological levels of cobalt and chromium are normally <0.25μg/L 
(0.005μM). Elevated levels of cobalt and chromium occur in both the hip synovial fluid and 
in peripheral blood after MOMHR. Whole blood concentrations of cobalt and chromium 
after MOMHR of up to 4.6μM and 2.3μM, respectively [8], and local hip synovial fluid levels 
of up to 30μM and 25μM, respectively, have been measured in-vivo [9]. Whilst circulating 
metal levels are usually highest over the first few months after implantation, persistent 
elevation occurs as late as 10 years after surgery [10].  
Previous studies have shown that short-term exposure to these metal species may 
affect human osteoclast and osteoblast survival and function. High concentrations of 
cobalt2+ (Co2+), chromium3+ (Cr3+), and chromium6+ (Cr6+) ions is toxic to osteoblasts and 
reduces cell activity in-vitro [11-13]. Few data are available on the effect of cobalt and 
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chromium exposure on primary human osteoclasts, although Nichols and Puleo showed 
short-term exposure to Co and Cr ions at sub-lethal doses resulted in decreased 
resorptive activity in rat osteoclasts [14]. In contrast, Rousselle et al. found exposure of 
rabbit osteoclasts to Cr3+ had no effect on rabbit osteoclast function [15]. Sankaramanivel 
et al. have shown that rats treated intraperitoneally with potassium dichromate (Cr6+) over 
5 days led to accumulation of chromium in the femur, and was associated with reduced 
systemic assays of alkaline phosphatase and tartrate-resistant acid phosphatase, 
suggesting an impact on both bone formation and resorption [16]. However, the longer-
term effect of chronic exposure of both human osteoblasts and osteoclasts to these ions at 
clinically relevant concentrations, more akin to clinical exposure both systemically and at 
the level of the hip joint, is unknown.  
We hypothesise that chronic exposure of local bone cells to metal ions may 
contribute to the clinical bone-related complications after MOMHR. The aims of this study 
were to investigate the effect of both short-term and chronic Co2+, Cr3+, and Cr6+ ion 
exposure at clinically relevant concentrations after MOMHR on human osteoblast and 
osteoclast proliferation and function, and on mature primary human osteoclasts. A dose-
ranging methodology was used including metal ion levels covering the normal 
physiological range, through systemic levels found after MOMHR, to the high 
concentrations reported in hip joint synovial fluid aspirates after MOMHR.  
 
2 MATERIALS AND METHODS 
2.1 Metal ion preparation and validation of concentrations 
Co2+ and Cr3+ were purchased as cobalt (II) chloride hexahydrate and Chromium (III) 
chloride hexahydrate from Sigma-Aldrich Company Ltd, Gillingham, UK. Cr6+ was 
purchased as chromium (VI) oxide from BDH, Lutterworth, UK. Stock solution for each 
metal ion at 0.2M was prepared in 50ml of sterile water and stored at 4°C prior to use. The 
Effect of metal ions on osteoblasts and osteoclasts 
5 
 
0.2M stock solutions were serially diluted in sterile distilled water to give aliquots of 100X 
the working concentration range for the treatment of cells. These were then diluted in 
Dulbecco’s modified Eagle’s medium (DMEM© GLUTAMAX™) supplemented with 0.5% 
FCS and 1% penicillin – streptomycin (10000units penicillin, 10000ug/ml streptomycin), 
which from here on will be referred to as vehicle. Control treatments were prepared to 
contain 1% of distilled sterile water in vehicle to maintain conditions, referred to as 0μM 
treatments. 
The final metal ion concentrations in the test solutions were confirmed using flame-atomic 
absorbance spectroscopy. Co2+, Cr3+ and Cr6+ predicted versus measured concentration 
showed close agreement (linear regression, r2 = 1.00, 0.85 and 0.98 for Co2+, Cr3+ and 
Cr6+, respectively). 
 
2.2 Osteoblast Cell Culture 
Human SaOS-2 cells (a human osteosarcoma-derived osteoblast cell line) were cultured in 
T75 flasks containing Dulbecco’s modified Eagle’s medium (DMEM© Glutamax™, Gibco® 
Invitrogen, Paisley, UK) supplemented with 10% FCS, 100 IU/mL of penicillin and 
100µg/mL of streptomycin (Sigma, Poole, UK), hereafter termed complete DMEM. The 
cells were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO2 until 
required for assay.  
 
2.3 Osteoblast Viability and Proliferation 
SaOS-2 cells were seeded at into 96-well plates at 5x103 cells per well in 0.1mL of 
complete DMEM and left to adhere overnight. The medium was then replaced with DMEM 
supplemented with 0.5% FCS and 100 IU/mL of penicillin and 100µg/mL of streptomycin 
(referred hereon in as vehicle) ± metal ion treatments and incubated for 3 or 13 days at 
37°C in a humidified atmosphere of 95% air and 5% CO2. Vehicle ± treatments were 
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replenished every 3rd and 4th day consecutively for cells cultured for 13 days. At the end of 
the culture period a CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay was 
performed according to the manufacturer’s instructions (Promega, Southampton, UK). The 
assay utilises dehydrogenase enzymes found in metabolically active cells to convert 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt (MTS) into an aqueous soluble formazan product. The absorbance of the 
formazan product produced by the cells was read at 490nm using a SpectraMax M5e 
Microplate Reader (Molecular Devices, Sunnyvale, CA). Values were expressed as 
percentage response relative to vehicle. 
 
2.4 Osteoblast synthetic function 
2.4.1 Alkaline Phosphatase (ALP) Activity 
SaOS-2 cells were seeded into 24-well plates at 15x103 cells per well in 1mL of complete 
DMEM, left to adhere overnight and then the medium was replaced with vehicle ± metal 
ion treatments and incubated for 13 days 37°C in a humidified atmosphere of 95% air and 
5% CO2. The vehicle ± treatments were replenished every 3rd or 4th day. Cells were 
washed with PBS, lysed in nuclease-free water and frozen at -80°C following completion of 
culture. Cell lysates were obtained after three freeze and thaw cycles. ALP activity was 
measured using p-nitrophenyl phosphate (pNPP) (Sigma) as the chromogenic ALP 
substrate in the presence of Mg2+ ions in a buffered solution. The absorbance was read at 
405nm using a SpectraMax M5e Microplate Reader. Values were expressed as 
percentage response relative to vehicle. DNA content was quantified using Quant-iT™ 
PicoGreen dsDNA Assay Kit (Invitrogen, Paisley, UK) according to the manufacturer’s 
instructions. ALP activity was normalized to DNA content and ALP/DNA was then 
expressed as percentage response relative to vehicle. 
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2.4.2 Osteoblast mineralization  
Once the SaOS-2 cells had reached confluency the cells were treated with vehicle 
supplemented with 10-8M Dexamethasone and 50µg/ml ascorbic acid (referred to as 
osteogenic medium) ± metal ion treatment. Metal ion treatments in osteogenic medium 
were changed every 3rd or 4th day. Two days prior to experiment end, 10µl of 5mM 
inorganic phosphate 4.2pH was added to the existing treatments within each well. On day 
21 cells were then washed once in PBS, fixed in 100% ethanol, rinsed in PBS and 
incubated in 40mM alizarin red (pH 4.2; Sigma) for 1 hour at room temperature. The cells 
were then washed extensively in 95% ethanol and air-dried. The plates were scanned on a 
high-resolution flat-bed scanner. The percentage of each well stained with alizarin red was 
quantified using Image J software (NIH: http://rsb.info.nih.gov/ij/) and expressed as 
percentage response relative to vehicle. 
 
2.5 Human Osteoclast Culture 
Osteoclasts were generated from human peripheral blood monocytes taken from healthy 
volunteers as previously described and with research ethics committee approval [17]. 
Sterilisation of 6mm diameter coverslips (Richardson’s of Leicester, Leicester, UK) was 
performed by baking at 180° for 2 hours. Dentine disks (http://www.dentinedisks.com/) 
were sonicated and sterilised by washing in 70% ethanol overnight. Venous blood was 
obtained from healthy volunteers and separated using Histopaque®-1077 (Sigma). The 
monocyte fraction was collected, washed and then re-suspended in α -MEM Glutamax 
(Gibco® Invitrogen, Paisley, UK). An appropriate volume of cell suspension containing 
5x105 cells was then added to pre-wetted coverslips or dentine disks in a 96 well plate. 
Cells were incubated for a minimum of 1 hour to allow adherence to the dentine or glass 
surface. Non-adherent cells were subsequently washed away with α -MEM. Adherent cells 
were incubated in 100µl α-MEM Glutamax containing 10% FCS, 100U/mL penicillin, 
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100µg/mL streptomycin (Sigma) (referred to as complete α -MEM) and supplemented with 
25ng/mL M-CSF, 30ng/mL recombinant RANKL (Insight Biotechnology, Wembley, UK) at 
37°C in a humidified atmosphere of 93% air and 7% CO2 for three weeks. To determine 
the effect of osteoclastogenesis metal ion treatments were added from day 3, whilst for 
effects on mature osteoclast activity metal ion treatments were added after the onset of 
resorption (typically 14 days). Complete α -MEM containing 25ng/mL M-CSF, 30ng/mL 
RANKL and treatments was replaced every 2-3 days. 
 
2.6 TRAP staining 
Dentine disks were TRAP stained as previously described [18, 19]. Briefly, the disks were 
fixed in 10% buffered formalin. Disks were then incubated in pre-warmed Acetate-tartrate 
buffer (0.1M Sodium tartrate (Sigma) in 0.2M Acetate buffer (Sigma), pH5.2) at 37°C for 5 
mins, followed by 30 mins incubation at 37°C in 20mg/mL Naphthol AS-BI phosphate 
(Sigma) /Dimethylformamide (Fisher Scientific, Loughborough, UK) in acetate-tartrate 
buffer. The disks were then incubated in acetate-tartrate buffer hexazotised pararosaniline 
solution. The disks were rinsed in water and counterstained in Gill’s haematoxylin. 
 
2.7 Quantification of Osteoclast Number and Resorption  
Resorbing osteoclasts were identified on dentine disks as a TRAP positive cell in or in 
close proximity to resorption pits and quantified from 8 random fields of view per disk. 
Resorption lacunae were identified in the same 8 random fields of view per disk and the 
plan area of resorption was determined by point counting as previously described[20]. All 
values were expressed as percentage response relative to vehicle. 
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2.8 Statistical Analysis 
All treatment comparisons were made versus vehicle (0µM). Logistic curve fitting was 
performed using the least squares (ordinary fit) method and a standard Hill slope to 
calculate IC50 values where effects on bone cell proliferation were found. Data sets were 
analysed using ANOVA with Dunnett’s multiple comparison post-test or the Kruskal-Wallis 
test with Dunn’s multiple comparison post-test, depending on the normality of the data 
distribution. All analyses were conducted 2-tailed using a critical p-value of 0.05 using 
GraphPad Prism® (GraphPad Software, La Jolla, CA). 
 
3 RESULTS 
3.1 Effect of short–term exposure to metal ions on osteoblast viability 
Treatment up to 2000µM of all ions caused a reduction in the number of viable, 
metabolically active osteoblasts compared to vehicle after 3 days (Figure 1, ANOVA 
p<0.0001). Cr6+ had the greatest effect on cell viability, and Cr3+ the least. The 
concentration above which there was a reduction in osteoblast viability was 100µM 
(p<0.001) for Co2+, 10µM for Cr6+ (p<0.0001), and 450µM for Cr3+ (p<0.0001). The ion 
concentration at which osteoblast viability was reduced by 50% (IC50 value), calculated by 
logistic curve fitting, was 135µM for Co2+, and 2.2µM for Cr6+. No IC50 was calculated for 
Cr3+ as 50% inhibition was not achieved over the clinical concentration range examined.  
 
3.2 Effect of chronic exposure to metal ions on osteoblast viability and function 
Osteoblast proliferation over 13 days was not affected by metal ion concentrations of Co2+ 
or Cr3+ up to 5µM (Figure 2A). However, Cr6+ at 1 and 5µM reduced osteoblast 
proliferation over 13-days exposure (p<0.05 and p<0.0001 respectively). These 
concentrations of Cr6+ had had no effect on short-term osteoblast proliferation.  
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ALP activity was reduced over 13 days exposure to all metal ions at 100µM (p<0.001 for 
Co2+; p<0.0001 for 135 and 175µM measured Cr3+ and Cr6+, respectively: Figure 2B). In 
addition, Cr6+ exposure also reduced ALP activity to undetectable levels at concentrations 
of 10µM and 1µM (p<0.05 and p<0.0001, respectively). When ALP activity was corrected 
for cell number using DNA content, only Cr6+ reduced ALP activity at the cellular level 
(10µM =p<0.05 and 100µM =p<0.001). Thus, the suppressed osteoblast activity was 
largely a function of reduced cell number rather than reduced activity per cell. 
Mineralisation activity, measured by Alizarin red staining after 21-days culture in 
osteogenic medium, was reduced with all metal ion treatments at 100µM (p<0.0001, 
Figure 2C). Cr6+ at 10µM also reduced mineralisation activity (p<0.0001). 
 
3.3 Effect of Co2+, Cr3+, and Cr6+ on osteoclastogenesis and resorption 
Treatment with Co2+ ions had no effect on osteoclast number from 0.01μM up to 
approximately 1µM (Figure 3A). The IC50 for C02+ was 12μM, and 200µM reduced the 
number of TRAP positive osteoclasts to near zero (p<0.0001). Total resorption followed a 
slightly different pattern, with a transient rise in resorption in the sub-micromolar range 
(EC50=0.4μM), followed by complete suppression of resorption at 200μM (Figure 3B and 
4A-C, P<0.001). Treatment with Cr3+ resulted in a biphasic response pattern for both 
osteoclast number and resorption (Figure 3A-B and 4D-F), with concentrations of up to 
approximately 0.1μM resulting on increased number (EC50 = 0.14μM) and resorption (EC50 
= 0.27μM). Above this concentration osteoclast number returned to physiological baseline 
and resorption declined to zero at [Cr3+ =200μM, P<0.001] (IC50 50μM). Cr6+ ions had the 
greatest inhibitory effect on the formation of functional osteoclasts. Increasing Cr6+ 
resulted in a reduction in the number of osteoclasts (IC50 = 0.37μM) and total resorption 
(IC50 = 0.30μM), (Figure 3A-B and 4G-I, p<0.0001 for 1µM to 100µM). 
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3.4 Effect of Co2+, Cr3+, and Cr6+ on mature, active osteoclasts 
To determine the effects of metal ions on mature, fully functional and active human 
osteoclasts, human monocytes were isolated, settled onto dentine disks and cultured as 
above but in the absence of metal ions to allow the fusion cells and formation of 
osteoclasts. The onset of resorption (an indicator of fully functional and active osteoclasts) 
was monitored daily from day 10 and once resorption had been detected (typically after 14 
days), the osteoclast culture medium was then replaced to include 0.01µM to 200µM Co2+ 
and Cr3+ and 0.01µM to 100µM Cr6+ ions for the last 7days of culture. The pattern of 
response for Co2+ and Cr3+ was different to that seen for newly forming osteoclasts in that 
no transient increase in cell number or activity was found, and that the inhibitory effects of 
all ions were seen at a lower ion concentration. Seven days treatment with Co2+ ions 
≥10µM reduced mature osteoclast number (IC50 = 5.4μM (p<0.001, Figure 3C). Total 
amount of resorption per disk was only reduced at the high (200µM) concentration 
(p<0.0001 and p<0.001, Figure 3D and 4J-L). Treatment with Cr3+ ions reduced mature 
osteoclast number and resorption per disk, but only at the 200µM dose (p<0.05, Figure 
3C-D and 4M-O, IC50 for osteoclast number = 221μM and IC50 for resorption per disk = 
77μM). No trend towards increased osteoclast number or resorption was seen for mature 
osteoclasts at the lower Cr3+ concentration range. Cr6+ ions had the greatest effect on 
osteoclast number and resorption. Cr6+ at concentration ≥10µM caused a reduction in 
osteoclast number and resorption per disk (P<0.01 all analyses, Figure 3C-D and 4P-R, 
IC50 for osteoclast number = 1.8μM and IC50 for resorption per disk = 3.9μM). 
 
 
4 DISCUSSION 
 
In this study we examined the effect of chronic exposure of human osteoblast and primary 
human osteoclast cells to Co and Cr ions at concentrations including the clinically 
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equivalent range defined by previous reports of measured metal levels in the serum and 
hip synovial fluid taken from patients after MOMHR. We found that ions of both metals 
affected osteoblast and osteoclast cell proliferation and function. These effects were 
greatest for Cr6+, then Co2+, with Cr3+ showing the least effect. The observed responses 
also varied with metal ion concentration, cell type and cell maturity.  
Our findings are consistent with in-vitro studies using animal cells that supra-
physiological concentrations of cobalt and chromium ions induce apoptosis in human 
osteoblast-like cells in-vitro in a dose-dependent manner [12], and suppress osteoblast 
synthetic function [11, 21, 22]. Our dose-ranging data suggest that chronic exposure to 
Co2+ or Cr3+ do not have a major effect on cell viability or synthetic function at 
concentrations equivalent to those metal levels found in serum or synovial fluid in patients 
after MOMHR, whilst exposure to Cr6+ has a profound effect on cell viability at 
concentrations equivalent to the serum chromium range after MOMHR. 
In contrast, our data suggest that an effect of Co and Cr on human primary 
osteoclasts occurs within the clinically observed concentration range and varies with cell 
maturity. At systemic levels these ions may have a mild stimulatory effect on developing 
osteoclasts, but at higher concentrations and in mature osteoclasts their effect is inhibitory. 
The reason for this difference might be explained by the substrate resorbing activity of the 
exposed cell, as mature resorbing osteoclasts may accumulate more intracellular metal 
ions through phagocytic activity versus developing osteoclasts, and thus demonstrate a 
greater toxic effect due to greater internalisation of the metal. In support of the increased 
resorption transient seen in the serum range, Patntirapong et al have shown that cobalt 
ions in solution or incorporated into calcium phosphate coated plastic at clinically-relevant 
concentrations increase murine osteoclast differentiation and resorption in-vitro [23]. Whilst 
cobalt ions do not localise to bone, chromium salts do have an affinity for bone [24], being 
trapped in the bone matrix, and thus levels in the bone microenvironment may exceed 
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those found in serum. Albrecht et al have also suggested a possible indirect route for 
osteoclast activation in response to metal ions, showing that exposure of human peripheral 
blood mononuclear cells to Co2+  ions in-vitro results in upregulation of IL-1α, IL-1β, and IL-
6 expression, that may in turn increase osteoclast birth rate and resorption [25]. 
Differences in the cellular responses to Co2+, Cr3+, and Cr6+ are likely complex, with 
several mechanisms operating. Co2+ and Cr6+ ion complexes are highly soluble and readily 
cross cell membranes via the anion transporter, whilst Cr3+ complexes are less soluble at 
physiological pH and cell membrane permeability to Cr3+ is low [26]. These physico-
chemical characteristics may explain, in part, the lower toxicity of Cr3+ relative to the other 
ions to both osteoblasts and osteoclasts. The high toxicity of Cr6+ may be explained by its 
rapid transport across cell membranes and subsequent reduction to Cr3+ within the cell by 
glutathione resulting in an increase in oxidative stress leading to cell death.[27]  
It is currently unclear which chromium species are released from prosthesis 
surfaces after MOMHR. Metal ion release as a result of corrosion, distinct to that arising 
from the process of wear, has been identified as a significant contributor to systemic metal 
release after MOMHR [7, 28]. Merritt and Brown have shown that Cr6+ is released during 
the corrosion of orthopaedic implants and is present systemically in-vivo [29]. However, De 
Flora et al have observed that circulating whole blood has a capacity to sequester and 
reduce approximately 200mg of Cr6+/day [30], which is in excess of that released from 
MOMHR bearings. Thus, bone cells in the prosthesis microenvironment may be subject to 
released Cr6+, and our data show that at clinically relevant levels this would be highly toxic 
to local osteoblasts and osteoclasts. A recent speciation study of chromium complexes by 
microfocus x-ray spectroscopy using a synchrotron beam in retrieved tissues around failed 
MOMHR prostheses showed chromium is present mainly as chromium (III) phosphate.[31] 
However, as Cr3+ has poor cell membrane permeability, its presence may arguably be 
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accounted for by its entering the cell as Cr6+ then being reduced to Cr3+, and giving rise to 
the necrotic lesions for which the biopsies were taken. 
Our observation of the toxicity of Co2+ to osteoclast cells at synovial fluid levels and 
to osteoblasts at concentrations 3-5 times that found in local tissues after MOMHR may 
occur through a similar mechanism to that observed in previous studies of lung toxicology. 
High concentrations of Co2+ are thought to induce cell damage by stabilising hypoxia 
inducible factors (HIF) that bind to DNA and initiate hypoxia-related gene expression and 
are normally degraded under normal oxygen tensions, resulting in HIF pathway activation 
and cellular apoptosis [32, 33]. 
Our observations that Co and Cr ions at clinically identified levels after MOMHR has 
several clinical implications for local bone health. Supressed osteoblast activity may 
explain early aseptic loosening as a failure of primary osseo-integration. In support of this 
concept, Long et al have reported a 15% failure rate for the Durom acetabular prosthesis 
in 207 hips within 2 years following implantation [34]. In all cases but 1 aseptic loosening 
of the prosthesis was the mode of failure, and in 13 prostheses examined in detail at 
retrieval, all showed failure of osseo-integration of bone onto the fixation surface. Femoral 
neck narrowing has commonly been reported after MOMHR and may contribute to fracture 
risk [35]. It has been suggested that narrowing occurs as a result of elevated hydrostatic 
fluid pressures in these patients, however, and alternative mechanism may be through 
osteoclast activation at the bone surface due to elevated metal levels. In support of this 
increased osteoclast numbers have been identified histologically on periosteal surfaces in 
fracture cases with femoral neck narrowing after MOMHR (Pat Campbell, personal 
communication). At a systemic bone health level, our data suggest that metal ions release 
may be sufficient to impact on osteoclast cell activity and number that in turn may affect 
bone mass and remodelling. The long term implication of systemic metal release after 
MOMHR for systemic bone health remains to be elucidated.  
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6 Legend to Figures 
Figure 1 Effect of metal ions on osteoblast viability. SaOS-2 cells were cultured with 
clinically relevant levels of Co2+, Cr3+ and Cr6+ for 3 days after which time a MTS assay 
was used to assess cell viability. All values expressed relative to vehicle (100%). n= 6 
wells per experiment, 3 replicate experiments. Values are mean ± SEM. Arrows represent 
upper limit of previously reported ion concentrations in-vivo. 
 
Figure 2 Effect of metal ions on osteoblast function. SaOS-2 cells were cultured for 13 
days after which time MTS assay was performed to assess proliferation (A) and ALP 
activity measured (B). Mineralisation was assessed in cells cultured in osteogenic medium 
in the presence of metal ions for 3-weeks (C). n= 3-6 wells per experiment, 3 replicate 
experiments. ap<0.05, bp<0.01, cp<0.001. (*spectroscopy measured concentrations were 
100µM for Co2+, 125μM for Cr3+, and 175μM for Cr6+). Line within boxes indicates median, 
boxes represent interquartile range, and whiskers are range. 
 
Figure 3 Effect of metal ions on human osteoclasts. A-B) Osteoclast formation. 
Monocytes were isolated from human peripheral blood, settled onto dentine disks then 
cultured with M-CSF and RANKL plus either Co2+, Cr3+ or Cr6+ ions for 21 days. C-D) 
Mature osteoclasts. Cells were cultured with M-CSF and RANKL for 14 days prior to the 
addition of metal ions (C-D). Cells were fixed and stained for TRAP with the number of 
osteoclasts and amount of resorption per dentine disk determined. n=5 wells per 
experiment, 3 replicate experiments. *p<0.05, **p<0.01, ***p<0.001. Logistic curve fitting 
was used to calculate the approximate EC50 and IC50 values. 
 
Figure 4. Metal ions and osteoclast number and dentine resorption. Peripheral blood 
mononuclear cells from healthy donors were cultured on dentine slices in recombinant M-
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CSF and RANKL-supplemented medium to generate multinucleated-osteoclasts. At day 
21, dentine slices were fixed in 10% buffered formalin, stained for tartrate-resistant acid 
phosphatase (TRAP) and counterstained with Gill’s haematoxylin. In ‘A’, the stars 
correspond to TRAP positive osteoclasts and the arrows point to the resorption pits.  Metal 
ions were introduced in the culture at day 3 (for A-I) at the indicated concentrations. For J-
R, metal ions were introduced once resorption was observed, generally day 14,  indicating 
mature osteoclasts.. Typical fields of view of cells following treatment; A-C and J-L treated 
with Co2+, D-F and M-O with Cr3+, G-I and P-R with Cr6+. Scale bar 200µm.   
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Figure 2 
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Figure 3 
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Figure 4 
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